Backed by Norwest.
About the role
Avalyn is seeking an experienced Senior Director, Head of Supply Chain to build and lead the company’s supply chain function as its clinical programs advance through later-stage development. Reporting to the SVP, Product Development, this leader will have end-to-end responsibility for clinical supply chain strategy and execution across Avalyn’s portfolio, with a focus on ensuring uninterrupted supply for complex global Phase 2 and Phase 3 clinical studies.
What they're looking for
- A minimum of a Bachelor’s degree in Supply Chain, Operations, Engineering, Life Sciences, Business, or a related discipline required, An advanced degree (i.e. MS, PharmD, PhD or equivalent) is preferred
- 12+ years of progressive supply chain experience in the pharmaceutical or biotechnology industry, with significant responsibility for clinical supply
- Direct Phase 2 and Phase 3 clinical supply experience required, including responsibility for complex, concurrent global clinical trials or programs
- Strong experience in demand forecasting, supply planning, inventory management, packaging and labeling, global distribution, depot strategy, and IRT/RTSM-supported supply planning
- Demonstrated experience integrating clinical demand with manufacturing, CMC, Quality, Regulatory, and program-level supply plans
- Significant experience managing outsourced clinical supply partners, including packaging, labeling, logistics, depots, distribution vendors, CDMOs, and manufacturing organizations
More about this role
Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. The company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects. Avalyn’s AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF). AP01 has demonstrated encouraging safety and clinical activity across Phase 1b and an ongoing, multi-year open-label extension trial, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone. Avalyn’s AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (IPF). Avalyn is also advancing AP03, an inhaled fixed-dose combination of pirfenidone and nintedanib, designed to deliver multiple antifibrotic mechanisms through a single lung-targeted platform. By leveraging its...
Browse similar: Startup jobs · Boston